Drs. Timothy Powell, Douglas Nixon, and Rodrigo Duarte have published a paper in Clinical & Translational Immunology that has identified three key inflammatory proteins that may be involved in the risk of acquiring severe COVID-19.
Dr. Julianne Imperato-McGinley is leading an effort to help make vaccination for COVID-19 available in trusted spaces within people’s own neighborhoods. It is estimated that 70 to 90% of the population needs to be vaccinated to reach herd immunity.
In a collaborative study, investigators have implemented advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases.
This exciting new program on COVID-19 for STEM students will cover many areas, including the dissemination of information about COVID-19 and vaccination for diverse communities, vaccine science, and approaches for community education.
Published in the Journal of the American College of Cardiology, Drs. Jonathan Weinsaft and Jiwon Kim have shown that an echocardiogram is a useful tool in evaluating COVID-19 patients who have damage to the heart’s right ventricle.
Dr. Brad Jones, Division of Infectious Diseases, began a collaboration several years ago involving T-cell therapy approaches to HIV that has played a key role in a breakthrough study on COVID-19.
These awards are supported by a grant from the Health Resources and Services Administration (HRSA) to the Weill Cornell Medicine Diversity Center of Excellence of the Cornell Center for Health Equity.
Investigators at Weill Cornell Medicine and NewYork-Presbyterian are recruiting 1,000 asymptomatic health care workers for a study on COVID-19 that seeks to answer the question: why do some people become severely ill, while others have no symptoms?
The WDOM congratulates three of its faculty - Drs. Julie Magarian Blander, Robert Peck, and Erica Phillips - who received grants from Weill Cornell Medicine in support of their innovative research on COVID-19.
Until now, vital data had been lacking on graft and patient outcomes in kidney transplant recipients and the management of their immunosuppression in the setting of Covid-19.